Pfizer's Says Company "Very" Big Balance Sheet for Deals
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
This article outlines scenarios where target date funds may be preferable to index funds in a 401(k), focusing on simplicity and risk management.
26,105 articlesPfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
A sharp one-day drop can leave investors anxious and markets buzzing. This guide breaks down the drivers behind super...
Analysts say Microsoft’s AI push is unlikely to threaten dividend safety inside Vanguard’s Dividend Appreciation ETF ...
XLY relies heavily on two megacaps, exposing the fund to outsized moves from Amazon and Tesla and prompting renewed q...
ARTY posted a 12-month gain of 28.3%, topping QQQ's 14.3% and SPY's 13.7%, as AI infrastructure exposure draws buyers...
Cathie Wood built a name on bold bets in disruptive tech. This piece breaks down how ARK Innovation rode dramatic swi...
Micron led gains in a tech-fueled rally as UBS boosted its price target on AI optimism. This article breaks down toda...
Public discourse and online search data can sway our money choices more than we realize. This article breaks down how...
As the United States hits its 250-year milestone, misinformation is reshaping how households spend, save, and invest....
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
The 2027 COLA could lift benefits, but rising Medicare costs and hold-harmless rules mean many retirees may see littl...
Three AI ETFs—CHAT, IGPT, and WISE—have consistently surfaced as thoughtful ways to own the generative AI theme, each...